Catalyst Pharmaceuticals Ownership | Who Owns Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals shareholders are primarily institutional investors at 83.02%, followed by 5.98% insiders and 11.00% retail investors. The average institutional ownership in Catalyst Pharmaceuticals's industry, Biotech Stocks , is 45.35%, which Catalyst Pharmaceuticals exceeds.

Catalyst Pharmaceuticals’s largest shareholders are Blackrock (18.69M shares, 16.01%), Deerfield management company, l.p. (series c) (9.13M shares, 7.81%), and Vanguard group (8.1M shares, 6.93%). Together, they hold 30.75% of Catalyst Pharmaceuticals’s total shares outstanding.

Yes, BlackRock owns 16.01% of Catalyst Pharmaceuticals, totaling 18.69M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 289.58M$. In the last quarter, BlackRock increased its holdings by 962.28K shares, a 5.43% change.

Tanaka capital management is Catalyst Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.62% of its assets in 153.39K Catalyst Pharmaceuticals shares, valued at 2.38M$.

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Catalyst Pharmaceuticals shares, with 5.96% of its total shares outstanding invested in 7.11M Catalyst Pharmaceuticals shares.